Upstream Bio, Inc.

Healthcare · Biotechnology · United States

Last price 3.27 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 179.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.